Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and
has become an urgent public health problem in most areas of the world. Substantial …

Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …

This review provides an overview of the three most widely used cholinesterase (ChE)
inhibitors: donepezil, rivastigmine, and galantamine. Differences in pharmacologic profiles …

Background: Cholinesterase inhibitors (ChEIs) are the only drugs marketed for the treatment
of Alzheimer's disease. Despite numerous randomized controlled trials, the efficacy and …

Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …

Background: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's
disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and …

Current pharmacological therapy for Alzheimer's disease (AD) includes the cholinesterase
inhibitors (ChEIs) donepezil, rivastigmine, and galantamine and the N-methyl d-aspartate …

Early research into Alzheimer's disease launched the cholinergic hypothesis, based on the
correlation between central cholinergic deficiency and clinical measures of cognitive …

Abstract Alzheimer's disease (AD), the most common cause of adult-onset dementia is
characterized by a progressive decline of cognitive functions accompanied by behavioral …

The current recommended standard of care for the symptomatic treatment of mild to
moderate Alzheimer's disease is cholinesterase inhibitors. In short-and long-term studies …